Alaska Permanent Fund, Altitude Life Science Ventures, and SoftBank Vision Fund 2 led a $230m Series B round in Tessera Therapeutics, an early-stage life sciences company, with participation from Qatar Investment Authority. "We are grateful to have support from world class investors in this funding round. The ability to write in the code of life will be a defining technology of this century and drive a fundamental change in medicine. Today’s support is a testament to Tessera’s outstanding team of scientists and our focus on bringing the extraordinary promise of Gene Writing to patients. We look forward to turning this powerful technology into a new category of medicines," Geoffrey von Maltzahn, Tessera Therapeutics CEO and Co-Founder.